The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death ...

Genitourinary oncologists discuss the safety and efficacy of IO/TKI and IO/IO combination therapies in advanced renal cell carcinoma. Tian Zhang, M.D., M.H.S.: In terms of front-line therapies, as we ...

Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital ...

Findings from the LITESPARK-005 trial showed a statistically significant improvement in progression free survival with belzutifan compared with everolimus. The Food and Drug Administration (FDA) has ...

Expert perspectives on the decision-making process for selecting frontline systemic therapy for patients with advanced renal cell carcinoma. Chandler H. Park, M.D.: One of the toughest parts of being ...

Development and Validation of an 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography–Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal ...

Credit: Getty Images. Belzutifan is a hypoxia-inducible factor inhibitor. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental News Drug Application (sNDA) for ...

Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...

MADRID -- Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older ...

Many medicines are available to treat kidney cancer. If one treatment doesn’t help or stops working, your health care provider may recommend another option. If you or a loved one has kidney cancer and ...